Advertisement
Screener

REVELATION BIOSCIENCES, INC. (REVB) Derivative Liability, Current

2.8 / 5 stars · 68/120 Roast Me

REVELATION BIOSCIENCES, INC. Derivative Liability, Current

REVELATION BIOSCIENCES, INC. (REVB) had Derivative Liability, Current of $2.39 million as of 2021-12-31, per its 10-K filed 2022-04-15.

Discontinued › Balance Sheet › Liabilities › Liabilities, Current

us-gaap:DerivativeLiabilitiesCurrent · last filed 2022-04-15

  • 2021-12-31: Derivative Liability, Current $2.39M.
  • 2021-09-30: Derivative Liability, Current $2.14M.
  • 2021-06-30: Derivative Liability, Current $2.23M.
  • 2021-03-31: Derivative Liability, Current $1.74M.
Period endDerivative Liability, Current
2021-12-31$2.39M
10-K · filed 2022-04-15
2021-09-30$2.14M
10-Q · filed 2021-10-29
2021-06-30$2.23M
10-Q · filed 2021-08-23
2021-03-31$1.74M
10-Q · filed 2021-06-22
2020-12-31$3.40M
10-K · filed 2022-04-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
HCW Biologics Inc. (HCWB)United States$0.004B-6.15
Onconetix, Inc. (ONCO)United States$0.004B
Aptevo Therapeutics Inc. (APVO)United States$0.003B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Sunshine Biopharma Inc. (SBFM)$0.003B
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Alaunos Therapeutics, Inc. (TCRT)United States$0.003B-1.44
Genprex, Inc. (GNPX)United States$0.003B-0.02
Silo Pharma, Inc. (SILO)United States$0.003B-1.57